Targets › SCGB2A1
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Aug 2028.
May bind androgens and other steroids, may also bind estramustine, a chemotherapeutic agent used for prostate cancer. May be under transcriptional regulation of steroid hormones. (UniProt, O75556)
Open in Phaseline: the race on SCGB2A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Washington University School of Medicine | Mammaglobin-A DNA Vaccine DNA vaccine encoding mammaglobin-A (SCGB2A1), a breast cancer-associated antigen; designed | SCGB2A1 | Phase 1 | Breast Cancer | Aug 2028 |
Breast Cancer (1)
other (1)
Washington University School of Medicine (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.